Quick Answer
Rani Therapeutics Holdings, Inc. reported Stockholders Equity of $33.01 million for fiscal year 2025.
Rani Therapeutics Holdings, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $33.01M | +1557.1% |
| 2024 | $1.99M | -84.5% |
| 2023 | $12.87M | -65.1% |
| 2022 | $36.85M | -22.3% |
| 2021 | $47.41M | +141.8% |
| 2020 | -$113.34M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$7.86M | -351.9% | -41.0% |
| June 30, 2025 | -$5.58M | -296.6% | -82.4% |
| March 31, 2025 | -$3.06M | -141.3% | -253.4% |
| December 31, 2024 | $1.99M | -84.5% | -36.2% |
| September 30, 2024 | $3.12M | -82.2% | +10.1% |
| June 30, 2024 | $2.83M | -88.2% | -61.7% |
| March 31, 2024 | $7.40M | -75.9% | -42.5% |
| December 31, 2023 | $12.87M | -65.1% | -26.7% |
- Rani Therapeutics Holdings, Inc. showed an increase of +1557.1% in Stockholders Equity compared to the prior fiscal year.
- Over the 2020–2025 period, Rani Therapeutics Holdings, Inc.’s stockholders equity has grown by 129.1% (from -$113.34 million to $33.01 million).
- The most recent figure is from Rani Therapeutics Holdings, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: